An eCTD dossier can be scientifically flawless and still fail at the door. Most submission delays are technical, not clinical — and nearly all of them are avoidable.
The electronic Common Technical Document is mandatory across all EU and EEA procedure types — centralised, decentralised, mutual recognition and national — as well as for Active Substance Master Files. Getting the mechanics right is a prerequisite to being assessed at all.
Know which specification applies
The EU Module 1 specification moved to version 3.1.1, and since 1 December 2025 only submissions compliant with it — and with validation criteria version 8.2 — are accepted. The underlying DTD did not change, so the practical impact is modest, but submitting against a superseded specification is an easy and entirely preventable rejection.
Where dossiers actually fail
- Reusing a sequence number to fix content. Content errors must never be corrected by resubmitting under the same sequence. The only accepted exception is an envelope error corrected at the agency’s request.
- Old PDF versions. PDF 1.3 or earlier is rejected outright.
- Stray files. Documentation and validation reports do not belong loose in the submission folder.
- Envelope metadata errors. These often pass validation but quietly break the lifecycle — the most expensive category, because the damage surfaces later.
- Mixing procedures. A single eCTD can never combine MRP/DCP and national products.
Note also that a Pass/Fail validation failure forces resubmission under the same sequence number — the one situation where reuse is correct.
Module 1: the regional detail
EU Module 1 carries the cover letter, application form, product information, expert information, environmental risk assessment, orphan market exclusivity information, pharmacovigilance and clinical trial information, and paediatric data. Section 1.0 — cover letter plus tracking table — is required in every submission for every procedure except EDQM.
What about eCTD v4.0?
Version 4.0 went live on 22 December 2025, but its scope today is narrow: it is optional and limited to new centralised marketing authorisation applications. Applicants must contact the EMA before making any v4.0 submission — a procedural gate, not a formality. Version 3.2.2 remains fully accepted, and rules for decentralised, mutual recognition and national procedures have not yet been written. No mandatory transition date has been published, so treat any date you see quoted with caution.
How PQRA helps
PQRA compiles, validates and maintains eCTD dossiers for the Greek and EU markets — and manages the lifecycle so that today’s submission does not become tomorrow’s problem.
No responses yet